Matching targeted therapies to gene mutations improves survival
Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared to those receiving non-matched, standard-of-care treatment, MD Anderson trial data revealed.
Long-term data from the center’s IMPACT trial, which compares treatments based on molecular profiling to standard-of-care treatments, showed the three-year, overall survival rate was 15 percent in those who underwent molecular profiling and 7 percent in those who did not. The 10-year survival rate was 6 percent in the molecular profiling group and 1 percent in the non-molecular profiling group.
This IMPACT study, which opened in 2007, is the first and largest precision medicine trial to look at survival.
Apostolia Tsimberidou, M.D., Ph.D., professor of Investigational Cancer
Therapeutics, presented a study at the ASCO Annual Meeting that shows
molecular profiling's benefit to patient survival. photo courtesy of ASCO